Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) will be posting its quarterly earnings results after the market closes on Thursday, November 7th. Individual interested in registering for the company’s earnings conference call can do so using this link.
Cumberland Pharmaceuticals Trading Up 0.9 %
Shares of CPIX traded up $0.01 during trading hours on Tuesday, hitting $1.15. The stock had a trading volume of 42,090 shares, compared to its average volume of 12,976. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.26 and a current ratio of 1.44. The firm has a market cap of $16.22 million, a P/E ratio of -1.58 and a beta of 0.22. The company’s fifty day simple moving average is $1.26 and its 200 day simple moving average is $1.42. Cumberland Pharmaceuticals has a 12-month low of $1.07 and a 12-month high of $2.36.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on Cumberland Pharmaceuticals in a research report on Saturday. They issued a “hold” rating on the stock.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
See Also
- Five stocks we like better than Cumberland Pharmaceuticals
- How Can Investors Benefit From After-Hours Trading
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Insider Buying Signals Upside for These 3 Stocks
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
